New advancements in artificial intelligence have the capacity to deliver major breakthroughs in cancer therapy.
AI-powered protein design company Profluent used AI to make an open-source gene editor called OpenCRISPR-1.
OpenCRISPR-1 can create molecules with the power to edit the human genome, according to Profluent.
Profluent’s aim is to develop gene editors that are more operative than existing biological mechanisms, especially mechanisms that prevent illnesses like cancer and fight viruses.
AI presenter Priya Lakhani joins The Context to explain this development in health and technology.
Subscribe here: http://bit.ly/1rbfUog
For more news, analysis and features visit: www.bbc.com/news
#Technology #Health #BBCNews
